BioXcel Therapeutics (BTAI)

• Market cap: $29.2M
• 1 day: -1.85%
• 5 days: -12.4%
• 1 month: -31.61%
• 3 months: -47.52%
• 6 months: -58.27%
• Year to date: -37.65%
• 1 year: -35.37%
• 5 years: -99.81%
• 10 years: -99.4%
• Sector: Healthcare
• Industry: Drug Manufacturers - Specialty & Generic

About: BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

Employees: 29